You are here: Industry Insights > Novartis

News List

Novartis plots 'innovative' payment models for pricey Luxturna's EU launch fiercepharma
November 27, 2018
It’s been almost a year since Spark Therapeutics won a groundbreaking gene therapy approval in the U.S. for Luxturna, and now its marketing partner Novartis has done the same across the pond.
Novartis scores new FDA nod, breakthrough tag for Promacta fiercepharma
November 26, 2018
When Novartis paid $16 billion to acquire GlaxoSmithKline’s cancer portfolio back in 2015, it picked up a few drugs that didn’t seem to have quite so clear growth prospects...
Novartis' gene therapy Luxturna becomes first approved European therapy for vision loss subtype pharmafile
November 26, 2018
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to be marketed...
GSK retains leading position on access to medicines list pharmatimes
November 22, 2018
GlaxoSmithKline has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
GSK retains leading position on access to medicines list pharmatimes
November 22, 2018
The 2018 Access to Medicine Index - which measures the performance of the top 20 pharma companies across seven different categories, such as access-to-medicine
FDA expands scope of Novartis’ Promacta pharmatimes
November 20, 2018
US regulators have expanded the scope of Novartis’ Promacta to include earlier use of the drug to treat adults and paediatric patients with severe aplastic
NICE issues final draft guidelines for Novartis’ Kymriah pharmatimes
November 19, 2018
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects fiercepharma
November 15, 2018
When Novartis said in June that it would spin off its long-struggling eye-care unit, Alcon, CEO Vas Narasimhan declined to estimate what the valuation on such a transaction might be.
Novartis' Entresto tops enalapril in stabilised heart failure patients pharmatimes
November 14, 2018
Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association's (AHA) scientific sessions, showing that the drug proved
Novartis says Entresto outperforms heart failure drug enalapril in key study firstwordpharma
November 13, 2018
Novartis presented study data at the American Heart Association's (AHA) scientific sessions showing that Entresto (sacubitril/valsartan) outperformed enalapril in patients with heart failure with reduced ejection fraction requiring hospitalisation for an

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page